Pharmaceutical
Manufacturing
Health

Akorn

$4.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-5.39%) Today
+$0.16 (3.84%) After Hours

Why Robinhood?

You can buy or sell Akorn and other stocks, options, ETFs, and crypto commission-free!

About

Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments. Read More The Prescription Pharmaceuticals segment manufactures and markets generic and branded prescription pharmaceuticals including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The Consumer Health segment offers branded and private-label animal health; and over-the-counter products. The company was founded in 1971 and is headquartered in Lake Forest, IL.

Employees
2,220
Headquarters
Lake Forest, Illinois
Founded
1971
Market Cap
507.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
3.02M
High Today
$4.35
Low Today
$4.03
Open Price
$4.30
Volume
593.26K
52 Week High
$19.65
52 Week Low
$2.64

Collections

Pharmaceutical
Manufacturing
Health
Health And Wellness

News

Seeking AlphaMay 20

FDA OKs Akorn antihistamine; shares ahead 2% after hours

The FDA approves Akorn's (NASDAQ:AKRX) Azelastine Hydrochloride Nasal Spray, 0.1%, a generic version of Moda's Astepro for the treatment of seasonal allergic rhinitis.

412
Yahoo FinanceMay 12

Here’s What Hedge Funds Think About Akorn, Inc.

While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions.

682
The Motley FoolMay 8

Akorn (AKRX) Q1 2019 Earnings Call Transcript

1,072

Earnings

-$0.70
-$0.39
-$0.08
$0.23
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.